| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/08/2022 | 7.9% | Piper Sandler | $65 → $40 | Downgrades | Overweight → Neutral |
| 11/18/2022 | 21.39% | Raymond James | → $45 | Initiates Coverage On | → Outperform |
| 11/14/2022 | 34.88% | Credit Suisse | $65 → $50 | Maintains | Outperform |
| 11/14/2022 | 75.34% | Piper Sandler | $70 → $65 | Maintains | Overweight |
| 08/25/2022 | 75.34% | Credit Suisse | → $65 | Initiates Coverage On | → Outperform |
| 05/16/2022 | 88.83% | Piper Sandler | $85 → $70 | Maintains | Overweight |
| 01/25/2022 | 237.2% | Oppenheimer | $141 → $125 | Maintains | Outperform |
| 08/10/2021 | 75.34% | Credit Suisse | $55 → $65 | Maintains | Underperform |
| 03/05/2021 | 277.66% | Piper Sandler | $135 → $140 | Maintains | Overweight |
| 02/01/2021 | 250.69% | Oppenheimer | $75 → $130 | Maintains | Outperform |
| 01/08/2021 | — | Credit Suisse | Downgrades | Neutral → Underperform | |
| 11/24/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 09/25/2020 | 13.3% | Credit Suisse | $13 → $42 | Maintains | Neutral |
| 08/20/2020 | 102.32% | Oppenheimer | → $75 | Initiates Coverage On | → Outperform |
| 07/27/2020 | -16.37% | Piper Sandler | $21 → $31 | Maintains | Overweight |
| 06/17/2020 | -43.35% | Piper Sandler | $18 → $21 | Maintains | Overweight |
| 05/29/2020 | -46.05% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/05/2020 | -70.33% | Credit Suisse | $12 → $11 | Maintains | Neutral |
| 11/05/2019 | -66.82% | Piper Sandler | $9.5 → $12.3 | Upgrades | Neutral → Overweight |
| 04/26/2019 | — | Credit Suisse | Downgrades | Outperform → Neutral | |
| 05/09/2018 | -86.51% | Credit Suisse | $6 → $5 | Maintains | Outperform |
| 03/01/2018 | — | Piper Sandler | Downgrades | Overweight → Neutral | |
| 03/01/2018 | -83.81% | Credit Suisse | $6.5 → $6 | Maintains | Outperform |
What is the target price for Fulgent Genetics (FLGT)?
The latest price target for Fulgent Genetics (NASDAQ: FLGT) was reported by Piper Sandler on December 8, 2022. The analyst firm set a price target for $40.00 expecting FLGT to rise to within 12 months (a possible 7.90% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fulgent Genetics (FLGT)?
The latest analyst rating for Fulgent Genetics (NASDAQ: FLGT) was provided by Piper Sandler, and Fulgent Genetics downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Fulgent Genetics (FLGT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulgent Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulgent Genetics was filed on December 8, 2022 so you should expect the next rating to be made available sometime around December 8, 2023.
Is the Analyst Rating Fulgent Genetics (FLGT) correct?
While ratings are subjective and will change, the latest Fulgent Genetics (FLGT) rating was a downgraded with a price target of $65.00 to $40.00. The current price Fulgent Genetics (FLGT) is trading at is $37.07, which is out of the analyst's predicted range.